Isomorphic Labs has closed a $2.1 billion Series B, the largest single funding round in AI-driven drug discovery to date, led by Thrive Capital with participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The round values a company that is, structurally, a bet on whether the same technology that solved protein folding can be pointed directly at designing new medicines rather than just describing existing biology.
This is not Isomorphic’s first outside check. The company raised its first external round, $600 million, in March 2025, also led by Thrive Capital with GV and follow-on capital from Alphabet, roughly fourteen months before this Series B. Thrive itself is a software-focused firm managing more than $50 billion in assets that has backed SpaceX, Stripe, and OpenAI, and leading both of Isomorphic’s outside rounds in barely a year signals a firm willing to concentrate capital heavily on a single conviction bet rather than spread it thinly across the AI-biotech field.
The company was spun out of Google DeepMind in 2021, led by DeepMind co-founder and CEO Demis Hassabis alongside president Max Jaderberg, built explicitly on the scientific foundation of the AlphaFold research program that won Hassabis and colleague John Jumper the 2024 Nobel Prize in Chemistry. The prize was actually split three ways: half went jointly to Hassabis and Jumper for AlphaFold’s protein-structure prediction, and the other half went to University of Washington biochemist David Baker for his separate work on computational protein design. That detail matters here because Baker went on to co-found Xaira Therapeutics, which raised a $1 billion debut round with no prior financing history, the largest first-time round ever recorded in AI drug discovery, meaning two of this year’s three Nobel laureates in the same prize now separately run two of the best-funded companies in the same emerging industry.
Isomorphic’s platform, IsoDDE, extends that structural-biology capability into protein-ligand interaction modeling, binding affinity prediction, and binding-pocket identification, the specific computational steps that determine whether a candidate drug molecule will actually bind to its intended target inside the body.
What separates this round from a typical AI-hype valuation is that Isomorphic already has paying pharmaceutical partners putting real money behind the platform’s output. Eli Lilly’s partnership includes a $45 million upfront payment with up to $1.7 billion in potential milestone payments tied to successful drug candidates. Novartis committed $37.5 million upfront in a separate partnership, and Johnson & Johnson signed on in January 2026. Those aren’t investment dollars, they’re pharmaceutical companies paying for access to Isomorphic’s drug-design pipeline on the belief that it will generate viable candidates faster or cheaper than conventional wet-lab discovery, which is a meaningfully different validation signal than a funding round alone provides.
The $2.1 billion will fund continued development of IsoDDE, push Isomorphic’s own therapeutic programs toward actual clinical trials rather than just computational candidates, and support hiring across the company’s sites in London, Cambridge, Massachusetts, and Lausanne. That geographic spread, anchored in the UK and Switzerland rather than concentrated in the Bay Area, reflects both DeepMind’s British origins and the reality that drug development regulatory expertise and pharmaceutical industry relationships remain heavily concentrated in Europe’s traditional life-sciences hubs.
Isomorphic isn’t operating in an empty field, and the rest of the AI-biotech funding landscape shows the same money chasing multiple approaches to the same problem. Recursion Pharmaceuticals built out its own combined platform by acquiring rival Exscientia for $688 million. Insilico Medicine took a different path entirely, raising roughly $293 million in a Hong Kong IPO in December 2025 on top of more than $500 million raised privately, and unlike most AI-drug-discovery companies it already has a clinical result to point to: its AI-discovered and AI-designed lung-disease drug candidate rentosertib posted a positive Phase IIa trial result published in Nature Medicine in 2025, an actual patient-outcome data point that neither Isomorphic nor Xaira has yet produced. Isomorphic’s bet, in other words, is that its Nobel-grade structural biology foundation eventually converts into the same kind of clinical proof, at a scale none of its well-funded rivals have matched yet.
Isomorphic’s raise lands inside a broader 2026 pattern of AI capital moving beyond pure software into capital-intensive physical and biological sciences, the same pattern visible in AI-infrastructure energy deals and inference-chip rounds elsewhere in this year’s funding data. Drug discovery is a particularly capital-hungry version of that trend: even with a faster computational front end, getting a molecule through preclinical testing and into human trials still costs hundreds of millions of dollars and takes years, meaning a round this size buys runway rather than results, and the real test of whether AI-designed drugs actually reach patients faster is still several years out, one that Insilico’s Nature Medicine result suggests is at least reachable.
The Philippine relevance here is genuinely indirect but not zero. The country has no domestic AI drug-discovery company remotely close to this scale, and the compute and specialized biology talent this space requires sit well outside what any Philippine startup could assemble today. But the Philippines does have a growing contract research and clinical-trial support industry serving global pharmaceutical clients, along with a large medical and life-sciences graduate talent pool that increasingly works remotely for exactly these kinds of international drug-development pipelines. As AI-native platforms like Isomorphic’s and its rivals generate more drug candidates that then need human clinical trial execution, patient recruitment, and regulatory-submission support, that downstream work is exactly the kind of high-skill outsourced service Philippine firms already compete for, and a faster AI-driven front end to drug discovery likely means more, not fewer, of those trials moving through the pipeline over the next decade.
The Philippine FDA and Department of Health have not yet published specific guidance on AI-designed therapeutics, an area regulators globally are still building frameworks for. As companies like Isomorphic, Xaira, Recursion, and Insilico move candidates from computational design into actual human trials over the next few years, and as at least one of them, Insilico, already has a published clinical result to point to, that regulatory gap will need to close well before any AI-originated drug could realistically reach a Philippine patient, a timeline worth tracking rather than an immediate concern, but one that starts the clock the moment a company at this funding scale begins moving candidates into the clinic.
Share this article